Osteoporosis Drugs

The Journal of the American Medical Association. 2008; 300 (24):2846

Author: Bridget M. Kuehn

An ongoing review of the safety of bisphosphonates has not found a link between the drugs and atrial fibrillation, according to an update issued by the US Food and Drug Administration (FDA) in November. The agency began reviewing the safety of this class of drugs in October 2007 after reports of elevated rates of atrial fibrillation in patients taking bisphosphonates emerged (Black DM et al. N Engl J Med. 2007;356[18]:1809-1822).

Bisphosphonates, including alendronate, etidronate, ibandronate, pamidronate, risedronate, tiludronate, and zoledronic acid, are used to treat osteoporosis, to slow bone turnover in patients with Paget disease, and to treat bone metastases and lower excess blood calcium levels in patients with cancer. The FDA examined data from clinical trials involving 19,687 patients taking these drugs and 18,358 patients taking a placebo. It found no clear association between bisphosphonate exposure and the rate of atrial fibrillation; it also found . . .

To purchase the full text, please click the link below:

Full Text of this Article




Upcoming Events


  • Wed
    29
    Mar
    2017

    Bone Matters - Unbreakable A Woman's Triumph over Osteoporosis

    12:30 - 1:30 pm EST
  • Mon
    03
    Apr
    2017
    Mon
    15
    May
    2017

    Break Through Program

    1:30 p.m. - 3:30 p.m.
  • Sat
    08
    Apr
    2017

    Bone Fit™ Clinical - Kitchener, ON

    7:30 am - 5:00 pm
  • Sun
    09
    Apr
    2017

    Bone Fit™ Clinical - Kitchener, ON

    8:00 am - 4:00 pm
  • Wed
    12
    Apr
    2017

    Bones N Beer - Peterborough ON

    6:30 pm
  • Sat
    13
    May
    2017

    Bone Fit™ Basics - Pickering, ON

    7:30 am - 5:00 pm
  • Sun
    14
    May
    2017

    Bone Fit™ Clinical - Pickering, ON

    8:00 am - 4:00 pm
  • Thu
    08
    Jun
    2017

    OSTEOPOROSIS LADIES GOLF CLASSIC

    All Day